Bernstein JL, Seminara D, Børresen-Dale, A-L. Workshop on The Epidemiology of the ATM Gene: Impact on Breast Cancer Risk and Treatment, Present Status and Future Focus, Lillehammer, Norway, 29 June 2002. Breast Cancer Res 2002; 4:249-252.
Bernstein JL, Teraoka S, Haile RW, et al. Designing and implementing quality control for multi-center screening of mutations in the ATM gene among women with breast cancer. Hum Mutat 2003; 21:542-500.
Bernstein JL, Bernstein L, Thompson WD, et al. ATM variants 7271T>G and IVS10-6T>G among women with unilateral and bilateral breast cancer. Br J Cancer 2003; 89:1513-1516.
Bernstein JL, Langholz BM, Haile RW, et al. Research Design: Evaluating gene-environment interactions in the etiology of breast cancer - the WECARE Study. Breast Cancer Res 2004; 6:R199-R214
Bernstein JL, Concannon P, Langholz B, et al. Multi-center screening of mutations in the ATM gene among women with breast cancer - the WECARE Study. Radiat Res 2005; 163:698-699.
Langholz B, Bernstein JL, Bernstein L, et al. On the proposed association of the ATM variants 5557G>A and IVS38-8T>C and bilateral breast cancer. Int J Cancer 2006; 119:724-725.
Langholz B, Thomas DC, Stovall M, et al. Analysis of radiation dose-response with tumor location and location-specific dose in the WECARE Study of second breast cancer. Radiation Research 2007; 167:358-359.
Largent JA, Capanu M, Bernstein L, et al. Reproductive history and risk of second primary breast cancer: the WECARE Study. Cancer Epidemiol Biomarkers Prev. 2007; 5:906-911.
Bertelsen L, Bernstein L, Olsen JH, et al. Effect of systemic adjuvant treatment on risk for contralateral breast cancer in the Women's Environment, Cancer and Radiation Epidemiology Study. J Natl Cancer Inst. 2008; 100(1):32-40.
Begg CB, Haile RW, Borg A, et al. Variation of breast cancer risk among BRCA1/2 carriers. JAMA 2008; 299(2):194-201.
Figueiredo JC, Bernstein L, Capanu M, et al. Oral contraceptives, post-menopausal hormones and risk of asynchronous bilateral breast cancer: The WECARE Study Group. J Clin Oncol. 2008; 26(9):1411-8.
Mellemkjær L, Dahl C, Olsen JH, et al. Risk for contralateral breast cancer among carriers of the CHEK2*1100delC mutation in the WECARE Study. Br J Cancer. 2008; 98(4):728-733.
Stovall M, Smith SA, Langholz BM, et al. Dose to the contralateral breast from radiation therapy and risk of second primary breast cancer in the WECARE study. Int J Radiat Oncol Biol Phys. 2008; 72:1021-1030.
Langholz B, Thomas DC, Stovall M, et al. Statistical methods for analysis of radiation effects with tumor and dose location-specific information with application to the WECARE Study of asynchronous contralateral breast cancer. Biometrics 2009;65(2):599-608.
Concannon P, Haile RW, Børresen-Dale A, et al. Variants in the ATM gene associated with a reduced risk of contralateral breast cancer. Cancer Research 2008; 15;68(16):6486-6491.
Knight J, Bernstein L, Largent J, et al. Alcohol intake and cigarette smoking and risk of a contralateral breast cancer in the Women's Environmental Cancer and Radiation Epidemiology Study. American Journal of Epidemiology February 11, 2009 [Epub ahead of print]
Figueiredo JC, Haile RW, Bernstein JL. Oral Contraceptives and Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. Current Breast Cancer Reports. June 2009
Figueiredo JC, Haile RW, Bernstein L, et al. Oral contraceptives and postmenopausal hormones and risk of contralateral breast cancer among BRCA1 and BRCA2 mutation carriers and noncarriers: the WECARE Study. Breast Cancer Res Treat. 2009 Jul 14. [Epub ahead of print]
Bernstein JL, Haile RW, Stovall M, et al. Radiation exposure, the ATM gene, and contralateral breast cancer in the WECARE Study. J Natl Cancer Inst. August 2009. [Accepted]